AU2022294711A1 - Combination therapy for the treatment of enteric neuropathies - Google Patents

Combination therapy for the treatment of enteric neuropathies Download PDF

Info

Publication number
AU2022294711A1
AU2022294711A1 AU2022294711A AU2022294711A AU2022294711A1 AU 2022294711 A1 AU2022294711 A1 AU 2022294711A1 AU 2022294711 A AU2022294711 A AU 2022294711A AU 2022294711 A AU2022294711 A AU 2022294711A AU 2022294711 A1 AU2022294711 A1 AU 2022294711A1
Authority
AU
Australia
Prior art keywords
combination
scfa
gdnf
use according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022294711A
Other languages
English (en)
Inventor
Nicolas Pilon
Rodolphe SORET
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus LP
Original Assignee
Transfert Plus SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus SC filed Critical Transfert Plus SC
Publication of AU2022294711A1 publication Critical patent/AU2022294711A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/124—Acids containing four carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022294711A 2021-06-16 2022-06-15 Combination therapy for the treatment of enteric neuropathies Pending AU2022294711A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202549P 2021-06-16 2021-06-16
US63/202,549 2021-06-16
PCT/CA2022/050955 WO2022261765A1 (en) 2021-06-16 2022-06-15 Combination therapy for the treatment of enteric neuropathies

Publications (1)

Publication Number Publication Date
AU2022294711A1 true AU2022294711A1 (en) 2023-12-21

Family

ID=84526051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022294711A Pending AU2022294711A1 (en) 2021-06-16 2022-06-15 Combination therapy for the treatment of enteric neuropathies

Country Status (8)

Country Link
US (1) US20240366723A1 (https=)
EP (1) EP4355354A4 (https=)
JP (1) JP2024523413A (https=)
KR (1) KR20240021837A (https=)
CN (1) CN117615776A (https=)
AU (1) AU2022294711A1 (https=)
CA (1) CA3220781A1 (https=)
WO (1) WO2022261765A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110440A1 (en) * 2013-01-10 2014-07-17 Biogen Idec Ma Inc. Methods for improved production and recovery of recombinant proteins from eukaryotic cell cultures
US20160045487A1 (en) * 2013-03-27 2016-02-18 Childeren's Medical Center Corporation Compositions and methods for treating neuropathy
CA3162011A1 (en) * 2019-12-19 2021-06-24 Rodolphe SORET Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Also Published As

Publication number Publication date
EP4355354A4 (en) 2025-04-09
WO2022261765A1 (en) 2022-12-22
JP2024523413A (ja) 2024-06-28
CN117615776A (zh) 2024-02-27
US20240366723A1 (en) 2024-11-07
CA3220781A1 (en) 2022-12-22
EP4355354A1 (en) 2024-04-24
KR20240021837A (ko) 2024-02-19

Similar Documents

Publication Publication Date Title
US8399408B2 (en) Method for treating diabetes using neurturin
JP6948250B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
ES2271968T3 (es) Receptor de factor neurotrofico derivado de linea celular glial.
JP2025084741A (ja) 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法
JP2013040204A (ja) コポリマー１と組み合わせた、神経発生の誘発及び幹細胞治療
JP2004532809A (ja) ホスホジエステラーゼ４型を阻害することによって、神経系の再生および修復を刺激するための方法
US8796199B2 (en) Uses of Cerberus and derivatives thereof
CN110869386A (zh) 重组神经生长因子的组合物和方法
AU2001233502B2 (en) Pancreatic islet cell growth factors
CN109715191A (zh) 将赘生性细胞转化成非赘生性细胞的药物缔合物及其用途
US20240366723A1 (en) Combination therapy for the treatment of enteric neuropathies
AU749530B2 (en) CNS neuroregenerative compositions and methods of use
EP4076499B1 (en) Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
US20080089868A1 (en) Retinal stem cell compositions and methods for preparing and using same
KR100409099B1 (ko) 신경 손상 치료 기구
US20230167444A1 (en) Compositions and methods for intranasal treatment with double stranded rna
WO2022046771A1 (en) Juvenile protective factors to arrest and reverse aging in the enteric nervous system
WO2015044379A1 (en) A dyrk1a polypeptide for use in preventing or treating metabolic disorders